Company
Every investor coverage indicates participated in a round AsclepiX Therapeutics raised.
Companies AsclepiX Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Steven M. Altschuler | Chair of the Board | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming AsclepiX Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eye-disease drug developer Azura Ophthalmics has appointed healthcare biotech veteran Steven Altschuler, a Ziff Capital Partners managing director and Spark Therapeutics co-founder, as chair of its board.